Probiotic Bifidobacterium reduces serum TMAO in unstable angina patients via the gut to liver to heart axis

Q2 Medicine

Liver Research Pub Date : 2025-03-01 DOI:10.1016/j.livres.2025.02.001

Zhihong Zhou , Lizhe Sun , Wei Zhou , Wen Gao , Xiao Yuan , Huijuan Zhou , Yuzhen Ren , Bihua Li , Yue Wu , Jianqing She

{"title":"Probiotic Bifidobacterium reduces serum TMAO in unstable angina patients via the gut to liver to heart axis","authors":"Zhihong Zhou , Lizhe Sun , Wei Zhou , Wen Gao , Xiao Yuan , Huijuan Zhou , Yuzhen Ren , Bihua Li , Yue Wu , Jianqing She","doi":"10.1016/j.livres.2025.02.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Studies indicate that the gut microbiota and its metabolites are involved in the progression of cardiovascular diseases, and enterohepatic circulation plays an important role in this progression. This study aims to identify potential probiotics for the treatment of unstable angina (UA) and elucidate their mechanisms of action.</div></div><div><h3>Methods</h3><div>Initially, the gut microbiota from patients with UA and control was analyzed. To directly assess the effects of <em>Bifidobacterium</em> supplementation, 10 patients with UA were enrolled and administered <em>Bifidobacterium</em> (630 mg per intake twice a day for 1 month). The fecal metagenome, serum trimethylamine N-oxide (TMAO) levels, and other laboratory parameters were evaluated before and after <em>Bifidobacterium</em> supplementation.</div></div><div><h3>Results</h3><div>After supplementing with <em>Bifidobacterium</em> for 1 month, there were statistically significant differences (<em>P</em> < 0.05) in TMAO, aspartate aminotransferase, total cholesterol, and low-density lipoprotein compared to before. Additionally, the abundance of <em>Bifidobacterium longum</em> increased significantly, although the overall abundance of <em>Bifidobacterium</em> did not reach statistical significance. The gut microbiota, metabolites, and gut-liver axis are involved in the progression of UA, and potential mechanisms should be further studied.</div></div><div><h3>Conclusions</h3><div>Metagenomic analysis demonstrated a reduced abundance of <em>Bifidobacterium</em> in patients with UA. Supplementation with <em>Bifidobacterium</em> restored gut dysbiosis and decreased circulating TMAO levels in patients with UA. This study provides evidence that <em>Bifidobacterium</em> may exert cardiovascular-protective effects through the gut–liver–heart axis.</div></div><div><h3>Clinical trial number</h3><div>ChiCTR2400093946.</div></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"9 1","pages":"Pages 57-65"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542568425000078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims

Studies indicate that the gut microbiota and its metabolites are involved in the progression of cardiovascular diseases, and enterohepatic circulation plays an important role in this progression. This study aims to identify potential probiotics for the treatment of unstable angina (UA) and elucidate their mechanisms of action.

Methods

Initially, the gut microbiota from patients with UA and control was analyzed. To directly assess the effects of Bifidobacterium supplementation, 10 patients with UA were enrolled and administered Bifidobacterium (630 mg per intake twice a day for 1 month). The fecal metagenome, serum trimethylamine N-oxide (TMAO) levels, and other laboratory parameters were evaluated before and after Bifidobacterium supplementation.

Results

After supplementing with Bifidobacterium for 1 month, there were statistically significant differences (P < 0.05) in TMAO, aspartate aminotransferase, total cholesterol, and low-density lipoprotein compared to before. Additionally, the abundance of Bifidobacterium longum increased significantly, although the overall abundance of Bifidobacterium did not reach statistical significance. The gut microbiota, metabolites, and gut-liver axis are involved in the progression of UA, and potential mechanisms should be further studied.

Conclusions

Metagenomic analysis demonstrated a reduced abundance of Bifidobacterium in patients with UA. Supplementation with Bifidobacterium restored gut dysbiosis and decreased circulating TMAO levels in patients with UA. This study provides evidence that Bifidobacterium may exert cardiovascular-protective effects through the gut–liver–heart axis.